DOB

# Research Output: DOB

## Chemical Identity

**PubChem-verified data (CID 62065):**
- IUPAC name: 1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine
- Molecular formula: C₁₁H₁₆BrNO₂
- Molecular weight: 274.15 g/mol
- InChIKey: FXMWUTGUCAKGQL-UHFFFAOYSA-N
- CAS number (racemate): 32156-26-6; HCl salt: 43061-15-0 / 43061-16-1 (enantiomers), 64638-07-9
- PubChem CID: 62065 [Ref 12 — PubChem API, api_verified]

**Physical properties (web-retrieved):**
- Melting point (freebase): 63–65°C [Ref 24]
- Melting point (hydrochloride salt): 207–208°C [Ref 24]
- Appearance: solid at room temperature

**SMILES: NOT API-CONFIRMED.** The PubChem API endpoint used does not return SMILES. The InChIKey (FXMWUTGUCAKGQL-UHFFFAOYSA-N) is confirmed; SMILES can be regenerated from InChIKey. Structurally derivable as `CC(N)Cc1cc(Br)c(OC)cc1OC` but this has not been programmatically verified. **FLAG: generation agent should derive SMILES from InChIKey or confirm via direct PubChem database query.**

**Seed data comparison:**
- Formula, MW, InChIKey confirmed against PubChem CID 62065.
- PubChem CID was absent from seed data — now confirmed as **62065**.
- SMILES was absent from seed data — still unconfirmed via API.
- IUPAC name in seed data was empty — now confirmed.

---

## Pharmacology

### Receptor Binding

DOB is a potent and selective agonist/partial agonist at serotonin 5-HT₂ receptor subtypes, primarily 5-HT₂A and 5-HT₂C, which is the basis for its hallucinogenic activity.

**5-HT₂ receptor binding affinity:**
- Racemate (±)-DOB: Kᵢ = 0.79 nM at [³H]DOB-labeled central 5-HT₂ serotonin receptors (Glennon et al. 1988 [Ref 1])
- R-(−)-DOB (active enantiomer): Kᵢ = 0.2 nM at 5-HT₂A (Glennon et al. 2004 [Ref 2])
- (R)-(−)-[⁷⁷Br]DOB as radioligand: KD = 0.60 ± 0.08 nM; Bmax = 1.2 ± 0.08 pmol/g tissue in rat cortical membranes (Peroutka et al. 1988 [Ref 3])
- S-(+)-DOB: significantly less active than R-(−) isomer in locus coeruleus potency ranking: (−)-DOB > DOM > (+)-DOB (Rasmussen, Glennon & Aghajanian 1986 [Ref 4])

**Receptor selectivity:**
- DOB (unlike its alpha-desmethyl analog 2C-B) shows high selectivity for 5-HT₂ receptors. The alpha-desmethyl derivative (alpha-desMe DOB) additionally binds 5-HT₁A, 5-HT₁B, and 5-HT₁C receptors with significant affinity, making it less selective than DOB (Glennon et al. 1988 [Ref 1]).
- A significant correlation (r = 0.89, p < 0.01) exists between drug potencies at (R)-(−)-[⁷⁷Br]DOB-labeled sites and human hallucinogenic potencies across a series of compounds (Peroutka et al. 1988 [Ref 3]).
- Drug affinities at [¹²⁵I]-R-(−)-DOI-labeled sites (tentatively designated as 5-HT₂A) showed high correlation with [⁷⁷Br]-R-(−)-DOB-labeled sites (r = 0.93, p < 0.01), confirming they represent similar/overlapping binding sites (McKenna & Peroutka 1989 [Ref 8]).
- NIMH-PDSP broad receptor screening indicates phenylalkylamines interact with up to 42 of 49 tested sites; DOB-class compounds are less selective than generally believed (Ray 2010 [Ref 7]).

**Functional pharmacology:**
- R-(−)-DOB behaves as a **partial agonist** with approximately 50% efficacy in a 5-HT₂-mediated calcium mobilization assay (Glennon et al. 2004 [Ref 2]).
- 5-HT₂A receptor activation involves both Gq/G₁₁ protein coupling and β-arrestin2 recruitment; structure-activity relationships for biased agonism at 5-HT₂A have been characterized for phenylalkylamine class (Pottie et al. 2023 [Ref 18]).
- The 2,5-dimethoxy motif is critical for in vivo potency. Removing either methoxy group from the DOB scaffold modestly reduces 5-HT₂A binding in vitro but significantly attenuates the head-twitch response in vivo, suggesting the dimethoxy motif plays a role beyond simple receptor binding (Marcher-Rørsted et al. 2020 [Ref 17]).

**In vivo potency:**
- DOB ED₅₀ = 0.75 μmol/kg in the mouse head-twitch response (HTR) assay, a validated behavioral proxy for serotonergic hallucinogen activity in rodents mediated by 5-HT₂A receptor activation. Bromo-DragonFLY (DOB's benzodifuran-constrained analog) had higher potency (ED₅₀ = 0.20 μmol/kg) (Halberstadt et al. 2019 [Ref 16]).
- In the locus coeruleus, potency rank order is: (−)-DOB > DOM > (+)-DOB. The inactive positional isomer SL-7161 did not affect LC unit activity, supporting selectivity of the effect (Rasmussen et al. 1986 [Ref 4]).
- DOB-labeled [³H]DOB radioligand labels 5-HT₂ receptors in an agonist high-affinity state; gives 10–100-fold higher affinities than antagonist radioligand [³H]ketanserin for agonist compounds (Lyon et al. 1988 [Ref 5]).

**In chronic spinal dog behavioral model:**
- DOB classified as "predominantly LSD-like with some amphetamine-like activity" — i.e., cross-tolerance to LSD but partial amphetamine-like pharmacology also demonstrable (Martin et al. 1978 [Ref 6]).

### Stereochemistry

The R-(−) isomer of DOB is the pharmacologically active eutomer. This is the same stereopreference as most phenethylamine hallucinogens and is determined by the absolute configuration at the alpha-methyl carbon (Glennon et al. 2004 [Ref 2]; Rasmussen et al. 1986 [Ref 4]). **This is opposite to MDMA and entactogens, where the S-(+) isomer is more active** (Nichols 2022 [Ref 11]).

### Pharmacokinetics

**No published human PK data for DOB exist.** The following is based on:
(a) The single published overdose case report (Balíková 2005 [Ref 9])
(b) Structural analog inference from 2C-B (alpha-desMe DOB) metabolism data (Carmo et al. 2005 [Ref 27])

- **Onset** (human, oral): Reported as 15 minutes to 3 hours in the overdose case and web sources; Shulgin (PIHKAL [Ref 13]) reports onset can take up to 3 hours; seed DB states 30–90 min
- **Duration** (human, oral): Shulgin (PIHKAL) documents 18–30 hours; seed DB lists 14–24 hours total. **FLAG: seed DB duration may underestimate typical duration; see Gaps & Flags.**
- **Serum concentrations in overdose**: 13 ng/mL (non-fatal, 113 kg) and 19 ng/mL (fatal, 65 kg) in serum on hospital admission following unknown ingestion time (Balíková 2005 [Ref 9])

### Metabolic Pathway (Inferred from 2C-B Analog Data)

No direct DOB metabolism studies in humans are published. 2C-B (4-bromo-2,5-dimethoxyphenethylamine), the alpha-desmethyl analog of DOB lacking the alpha-methyl group, has been studied:

- **Phase I metabolism of 2C-B** (Carmo et al. 2005 [Ref 27]):
  - **Oxidative deamination** → 2-(4-bromo-2,5-dimethoxyphenyl)ethanol (BDMPE) and 4-bromo-2,5-dimethoxyphenylacetic acid (BDMPAA)
  - **O-demethylation** of the dimethoxy groups
  - 4-bromo-2,5-dimethoxybenzoic acid (BDMBA) produced by further oxidative deamination
  - Interspecies differences: humans form 2-(4-bromo-2-hydroxy-5-methoxyphenyl)ethanol (B-2-HMPE) — not formed by dogs, rats, mice
  - Large inter-individual variation between human donors noted
- **DOB-specific considerations**: The alpha-methyl group makes DOB an amphetamine. Additional pathways expected include:
  - Alpha-ketone formation (as with methamphetamine/amphetamine)
  - N-hydroxylation
  - CYP2D6 involvement (by analogy with ring-substituted amphetamines; Kuwayama et al. 2012 [Ref 11 — note: ref for MDMA CYP2D6 data, analog inference])
  - MAO-catalyzed deamination

**FLAG: No CYP-specific DOB metabolism data published. All above is analog inference, not substance-specific evidence.**

---

## History

### Discovery and Synthesis

DOB was first synthesized by Alexander Shulgin in approximately 1967, and was first described in the scientific literature in 1971, predating its scheduling. It is a member of the DOx class of phenethylamine hallucinogens — a family of 2,5-dimethoxyamphetamines bearing a variable substituent at the 4-position of the aromatic ring ([Ref 13] — Shulgin PIHKAL, unverifiable book; [Ref 12] — bionity.com web source).

The parent DOx class became known following the identification and first human trial of DOM (2,5-dimethoxy-4-methylamphetamine, "STP") by Snyder, Faillace & Hollister in 1967, who showed it was approximately 100× more potent than mescaline as a hallucinogen (Snyder et al. 1967 [Ref 25]).

**Discrepancy flag:** A cached abstract from Glennon & Dukat 2024 [Ref 26] states "DOI, DOC, DOB all first synthesized 1973," which conflicts with web-sourced accounts of Shulgin synthesizing DOB in 1967 and it being described in literature in 1971. This discrepancy likely reflects that Glennon synthesized DOI in 1973 in a structure-activity series, while DOB was synthesized earlier by Shulgin. The Federal Register scheduling (September 1973) also implies prior public knowledge. **FLAG: Generation agent should flag synthesis date discrepancy and note two accounts for editorial review.**

### INN Designation

The WHO proposed and recommended "brolamfetamine" as the International Nonproprietary Name (INN) for DOB in 1986 [Ref 24].

### Regulatory Timeline

- **US Schedule I**: Effective September 21, 1973 (Federal Register 38 FR 26447) [Ref 22]. This is among the earliest phenethylamine hallucinogens to be federally scheduled.
- **UK**: Class A under the Misuse of Drugs Act 1971, explicitly controlled as 4-bromo-2,5-dimethoxy-α-methylphenethylamine [Ref 23].
- **Canada**: Schedule I under the Controlled Drugs and Substances Act [Ref 24].
- **Australia**: Schedule 9 (prohibited substance) under the Poisons Standard [Ref 24].
- **International**: Schedule I of the UN Convention on Psychotropic Substances [Ref 24].

### PIHKAL Documentation

Alexander Shulgin documented DOB's synthesis, pharmacological effects, and dosing extensively in *PIHKAL: A Chemical Love Story* (1991) [Ref 13]. DOB appears among the most potent compounds described in PIHKAL. Shulgin lists dosage range as 1–3 mg for the racemate with effects lasting 18–30 hours.

**Note on "characterization" field:** The seed data lists DOB as "emerging" but DOB has been federally scheduled since 1973 and has a documented history spanning 50+ years. This field may require updating to "established" or "classic" by editorial review.

---

## Subjective Effects

No controlled human pharmacology trials for DOB have been published. Subjective effect documentation derives from:

1. **Shulgin self-reports** (PIHKAL, 1991 [Ref 13]) — Primary source for human dosing and phenomenology
2. **Overdose case report** (Balíková 2005 [Ref 9]) — Pathological/toxic presentation
3. **Drug discrimination studies in rats** (Glennon 1986, 1988 [Refs 10, 1]) — Behavioral analog of subjective states
4. **Chronic spinal dog model** (Martin et al. 1978 [Ref 6]) — Classification as predominantly LSD-like

### Documented Effect Profile

**General character:** DOB produces hallucinogenic effects classified as predominantly LSD-like with some amphetamine-like stimulant activity (Martin et al. 1978 [Ref 6]; Nichols 2016 [Ref 14]). Drug discrimination studies confirm R-(−)-DOB produces stimulus effects mediated by 5-HT₂ receptors, with cross-generalization between DOB, DOM, and DOI in trained animals (Glennon et al. 1988 [Ref 1]; Glennon 1986 [Ref 10]).

**Hallucinogenic effects:** DOB induces hallucinations, described in the overdose case as "intense hallucinations" with onset ~15 minutes after ingestion (Balíková 2005 [Ref 9]). Effect taxonomy listed in seed data (visual hallucinations, synesthesia, tracers, object transformations, color alterations, etc.) is consistent with the 5-HT₂A mechanism [Ref 14] but derives from community/self-report, not controlled study.

**Stimulant effects:** Amphetamine scaffold and monoamine-releasing class pharmacology predicts sympathomimetic stimulant effects (tachycardia, hypertension, hyperthermia, vasoconstriction). Consistent with Martin et al. 1978 "some amphetamine-like action" classification.

**Duration:** Shulgin documents 18–30 hours total duration [Ref 13]. This is notably longer than most psychedelics including LSD (~8–12 h) and consistent with the class property of DOx compounds. **See dose/duration section flag below.**

### Dose Data

From Shulgin (PIHKAL [Ref 13]):
- Dosage range: 1–3 mg (racemate, oral)
- Enantiopure R-(−)-DOB effective at approximately half this dose
- Seed DB values (threshold 0.2 mg; light 0.2–0.75 mg; common 0.75–1.75 mg; strong 1.75–3 mg; heavy 3+ mg) are broadly consistent with PIHKAL data

From overdose case: "effective dose estimated at 2 mg for an 80 kg man" [Ref 9]. Given that the non-fatal patient weighed 113 kg and the fatal patient 65 kg at unknown ingested doses, this estimate from the report aligns with the 2–3 mg range for a strongly psychoactive dose.

---

## Safety & Toxicity

### Confirmed Overdose Case Report

Balíková (2005) [Ref 9] presents the only published confirmed DOB overdose case — two men who co-ingested an unknown quantity of a designer drug sold as "LSD-like":

- **Onset:** Intense hallucinations after ~15 minutes; vomiting
- **Progression:** Both became unconscious and fell into deep coma lasting several days
- **Toxicological analysis:** DOB confirmed by GC-MS in gastric and urine samples; DOB-targeted analysis with acetylated analyte confirmed in both subjects
- **Serum concentrations on hospital admission:** 13 ng/mL (Subject AX, 113 kg, survived); 19 ng/mL (Subject BX, 65 kg, died)
- **Clinical course of fatal case (BX):** Convulsions, metabolic acidosis, death on day 6
- **Co-substances:** Ethanol <0.2 g/kg; THCOOH and cocaine in Subject AX urine only; amphetamine immunoassay negative in both
- **Note:** This is the first documentation of DOB consumption in the Czech Republic and the first published case of confirmed DOB fatality

**Effective dose context from case:** Authors estimate effective dose as ~2 mg for 80 kg person [Ref 9], placing the toxic/fatal dose in close proximity to the active dose — a narrow therapeutic window consistent with Shulgin's high-potency classification.

### Vasoconstriction

High doses of DOB are associated with serious vasoconstriction of the extremities [Ref 24 — Bionity/web sources]. This is a class property shared by DOx compounds and their more potent analogs (Halberstadt 2017 [Ref 15]; Corazza et al. 2011 [Ref 19]). The related compound Bromo-DragonFLY (a constrained analog of DOB) has been specifically associated with arterial vasospasm and limb ischemia fatalities [Ref 19]. Vasoconstriction at 5-HT₂A/2B receptors in vascular smooth muscle is the likely mechanism.

### Toxicity Data

- **Toxic dose (humans):** Unknown; serum 19 ng/mL associated with fatality in one case [Ref 9]
- **LD50:** Not established for humans; no animal LD50 data found in published literature
- **Safety margin:** Extremely narrow based on overdose data; active dose 1–3 mg, fatality occurred at estimated overdose in similar dose range
- **Convulsions and metabolic acidosis:** Documented in fatal case [Ref 9]
- **Coma:** Both overdose patients; duration several days [Ref 9]
- **No organ-specific toxicity data** beyond the one case report

**FLAG: No LD50 published. No controlled toxicology data. Toxic dose cannot be precisely specified from available literature.**

### Psychological Risks

As a potent 5-HT₂A agonist, DOB shares the class-wide psychological risks documented for serotonergic psychedelics: anxiety, panic, paranoia, and thought disorder, particularly at higher doses or in unprepared contexts (Nichols 2016 [Ref 14]). The very long duration (18–30 hours) significantly increases exposure to psychological stress and reduces the ability to terminate unwanted effects.

---

## Harm Reduction

### Duration Warning

The most critical harm reduction consideration for DOB is its **exceptionally long duration** (18–30 hours per Shulgin [Ref 13]), significantly exceeding user expectations based on comparisons with LSD. The drug is commonly distributed on blotter paper and may be misrepresented as LSD; a user expecting an 8–12 hour LSD experience who has instead taken DOB may be trapped in an unexpectedly prolonged and distressing state.

### Dose Sensitivity

DOB is active at milligram doses (1–3 mg, [Ref 13]). The margin between a psychoactive dose and an overdose is extremely narrow based on the Balíková 2005 case [Ref 9]. Accurate weighing with a precision milligram scale is critical.

### Drug Checking / Identification

DOB (and DOx compounds) can be analytically identified by:
- UPLC-QTOF-MS: characteristic product ions at m/z 178.0994, 163.0754, 147.0804, 135.0810 for DOx class (Pasin et al. 2017 [Ref 20])
- Immunoassay: **negative** for amphetamines in the overdose case [Ref 9] — standard urine drug screens will NOT detect DOB
- GC-MS with acetylation: method used in the Balíková 2005 confirmation [Ref 9]
- Reagent testing: DOB reacts with Ehrlich reagent (negative — not an indole), Simon's reagent (negative — primary amine, no secondary N-methyl), and Marquis reagent

### Vasoconstriction Risk

High-dose DOB: significant vasoconstriction risk [Refs 15, 19, 24]. Seek emergency medical attention for signs of compromised circulation in extremities.

### Emergency Response

If overdose suspected: emergency services immediately. Standard toxicology screens will not detect DOB — clinicians should be informed of suspected specific substance. GC-MS targeted analysis required for confirmation.

---

## Tolerance & Dependence

### Tolerance

DOB is a serotonergic psychedelic and exhibits the class-wide property of rapid tolerance (tachyphylaxis) to its hallucinogenic effects following repeated administration. This is mediated by 5-HT₂A receptor downregulation and desensitization following sustained agonist exposure (Nichols 2016 [Ref 14]).

**No DOB-specific tolerance kinetic data published.** Seed DB values (tolerance buildup: almost immediately; half-life: 5.5 days; full reset: 8.5 days) are consistent with class-based inference from data on DOM/DOI/LSD/psilocybin tolerance but are **not supported by published DOB-specific studies**. These values derive from self-report community databases by analogy. **FLAG: Tolerance timing data needs editorial attribution/sourcing.**

### Cross-Tolerance

DOB shares cross-tolerance with other serotonergic psychedelics acting via 5-HT₂A receptors. Chronic SSRI administration downregulates 5-HT₂A receptors and attenuates the subjective effects of serotonergic hallucinogens (Bonson et al. 1996 [Ref 21]). This is the basis for reduced DOB effects in chronic SSRI users.

### Dependence

No published evidence for physical dependence on DOB. Serotonergic psychedelics as a class are not considered habit-forming and do not produce compulsive use patterns or withdrawal syndromes (Nichols 2016 [Ref 14]).

---

## Interactions

### Tramadol (Listed as "Dangerous" in Seed Data)

Tramadol inhibits serotonin and norepinephrine reuptake and stimulates serotonin release, in addition to opioid receptor activity. Combined with a potent 5-HT₂A agonist like DOB, this combination raises theoretical risk of serotonin excess effects. **No published case reports or studies of tramadol + DOB specifically found.** The "dangerous" designation in seed data is a class-based pharmacological inference, not a substance-specific published finding.

**FLAG: Tramadol + DOB interaction is pharmacologically plausible but unconfirmed by specific published evidence. This should be labeled as class-based inference.**

### SSRIs / SNRIs

Chronic SSRI use downregulates 5-HT₂A receptors and may significantly attenuate or abolish DOB's psychedelic effects (Bonson et al. 1996 [Ref 21]). Acute SSRI/SNRI co-administration raises theoretical serotonergic toxicity concerns, though no published case reports for DOB specifically.

### MAO Inhibitors (MAOIs)

MAOIs reduce the oxidative deamination of amphetamine-type compounds, potentially increasing exposure to DOB and its active form. Combined with serotonin-releasing properties, MAOIs + DOB represent a significant risk of serotonin excess. No published studies found for DOB specifically; class inference from amphetamine pharmacology.

### Cannabis

Seed data lists "Cannabis: unknown" interaction. No published interaction data found. Pharmacologically, cannabis's 5-HT₂A modulatory effects (CB1 receptor-5-HT₂A crosstalk documented) could theoretically alter DOB response. **No evidence base for specific interaction severity.**

---

## Legal Status

| Jurisdiction | Status | Schedule/Class | Date |
|---|---|---|---|
| United States | Illegal | Schedule I (21 CFR 1308.11(d)) | September 21, 1973 (38 FR 26447) [Ref 22] |
| United Kingdom | Illegal | Class A, Misuse of Drugs Act 1971 | Named explicitly [Ref 23] |
| Canada | Illegal | Schedule I, Controlled Drugs and Substances Act | [Ref 24] |
| Australia | Illegal | Schedule 9 (Prohibited substance), Poisons Standard | [Ref 24] |
| International | Illegal | Schedule I, UN Convention on Psychotropic Substances | [Ref 24] |

---

## Clinical Trials

**No clinical trials registered for DOB on ClinicalTrials.gov.** Search query "DOB brolamfetamine 4-bromo-2,5-dimethoxy amphetamine" returned zero results. This is expected for a Schedule I compound with no approved medical applications and no active research program.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Safety-Critical Flags (Require Human Review)

1. **Duration discrepancy — HIGH PRIORITY:** Seed DB lists total duration as 14–24 hours. Shulgin's PIHKAL documents 18–30 hours. Shulgin is the primary source of DOB human experience and PIHKAL is the canonical reference. The seed DB values may **underestimate** typical duration by 4–6 hours. Given the critical safety significance of duration (avoiding dose redosing, managing unexpected prolonged states), this should be reviewed and likely revised upward.

2. **Tramadol interaction lacks specific evidence:** The "Tramadol: dangerous" designation in seed data is a pharmacological class inference, not confirmed by published DOB-specific case reports or studies. Should be labeled with confidence qualifier.

3. **Toxic dose unknown:** No published LD50. One confirmed fatal case (serum 19 ng/mL, unknown ingested dose). No safe upper dose limit can be specified from published data.

4. **Tolerance timing data (5.5-day half-life, 8.5-day full reset):** Not from published DOB-specific studies. Class-based inference from broader psychedelic tolerance literature. Should be noted as estimated.

### Data Gaps

5. **SMILES not API-confirmed:** PubChem API did not return SMILES for CID 62065 (requires JavaScript rendering). InChIKey FXMWUTGUCAKGQL-UHFFFAOYSA-N confirmed. Generation agent should derive SMILES from InChIKey.

6. **No published human pharmacokinetic data for DOB:** No Tmax, half-life, bioavailability, protein binding data available. All PK is inferred from case report serum levels and structural analog data (2C-B metabolism, Carmo et al. 2005).

7. **No published DOB-specific metabolism studies:** CYP enzyme involvement is inferred from amphetamine analogs (CYP2D6 likely; MAO involvement) and from 2C-B hepatocyte data.

8. **No controlled human pharmacology study:** All subjective effect documentation for DOB comes from Shulgin's self-reports (PIHKAL, 1991) and extrapolation from animal models. No double-blind human studies published.

### Potential Seed Data Errors

9. **"Bromo-DMA" as street name — VERIFY:** The brief lists "Bromo-DMA" as a street-name candidate. This designation could refer to 4-Bromo-3,5-dimethoxyamphetamine, which is a different chemical from DOB (2,5- vs 3,5-dimethoxy substitution). If "Bromo-DMA" is intended as informal shorthand for "bromo-dimethoxy-amphetamine" (i.e., DOB itself), that is distinct from 4-Br-3,5-DMA. **FLAG for editorial clarification.**

10. **"Emerging" characterization is likely incorrect:** DOB has been federally scheduled since September 1973, is documented extensively in PIHKAL (1991), and has established pharmacology published since 1978. Characterization should likely be "classic" or "established."

11. **Synthesis date discrepancy:** Web sources (Bionity, derivative Wikipedia) cite Shulgin ~1967 first synthesis. Cached abstract from Glennon & Dukat 2024 states "DOI, DOC, DOB all first synthesized 1973." This is an important historical discrepancy that affects the article's history section. Likely explanation: Shulgin synthesized DOB first (~1967); Glennon independently synthesized DOI in 1973 in a structure-activity series and the abstract may misrepresent when specific compounds were first made vs. first reported by Glennon's group. Full text of Glennon & Dukat 2024 [Ref 26] should be consulted to resolve.

### Sections Relying on Structural Analogy

12. **Metabolic pathway section** relies on 2C-B analog data [Ref 27], not DOB-specific studies.
13. **CYP enzyme involvement** inferred from broader amphetamine pharmacology.
14. **Tolerance kinetics** inferred from psychedelic class data.
15. **Drug interaction severity ratings** (tramadol, cannabis) based on pharmacological reasoning, not substance-specific published evidence.